Board summary
Key figures
87,308
Registered population
60.4% aged 18–64
20.2%
Aged 65+
ICB 19.0% · England 17.9%
4.0%
Ethnic minority (non-White)
1.8% Asian · England 9.6%
42.9%
In IMD quintile 1
ICB 31.9% · England 21.0%
~39,044
Core20 residents (est.)
Resident basis; registered basis ~38,685 · see page 3
15,893
Hypertension register
+5.90% in 3 yrs · England +5.60%
1,078
SMI register
47.4% of St. Helens (LAD)'s
2,462
COPD register
Reviews +9.31% in 3 yrs
Forecast to 2030
18,080
Hypertension patients, 2030
+2,187 on today
74.6%
QRISK ≥20% on statins, 2030
+4.69pp over 3 yrs
4.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Annual asthma reviews lag behind England.
Only 54.5% of the 6,668 asthma register had an annual review (England 65.7%, St. Helens 58.2%), leaving about 3,000 patients unreviewed.
MMR coverage trails the 95.0% target.
In Q1 2025/26, 24-month MMR1 is 83.3% (England 88.3%), and age-5 coverage differs by 7.4 pp between MMR1 (95.8%) and MMR2 (88.4%).
Breast screening coverage exceeds all comparators.
Breast screening for ages 53 to 70 reached 74.0% (St. Helens 73.1%, ICB 72.0%, England 69.9%), rising +10.8% over 2023 to 2024 (England +8.4%).
Population, age and ethnicity
Patients aged 65+ account for 20.2% of registrations, exceeding England while list growth lags
Across 87,308 registered patients, 20.2% (17,608) are aged 65+, compared with 20.1% in St. Helens, 19.0% in the ICB and 17.9% in England, while children aged 0-17 comprise 19.5% (16,997). Projected list growth to 2030 is 1.3% under an unverified model, trailing St. Helens (1.6%), the ICB (2.3%) and England (2.3%). Based on resident Census data rather than GP registrations, 96.0% are White and 4.0% identify with ethnic minority groups (Asian 1.8%, Mixed 1.1%, Other 0.6%, Black 0.5%). This older profile may concentrate routine chronic disease management across primary care.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are St. Helens (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (St. Helens LA) | 2,208 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.1% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 53.7% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (St. Helens LA) | 1,143 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (St. Helens LA) | 24.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 42.9% across the PCN but varies sharply across member practices
Across the PCN, 42.9% of registered patients live in Core20 areas, exceeding St. Helens (38.5%), the ICB (31.9%) and England (21.0%), with an average IMD decile of 4.3 (England 5.5). Weighted practice share is 44.3%, showing a 1.45 percentage point reconciliation discrepancy. Across captured practices, the Core20 cohort spans a range of 84.7 pp. Berrymead Family Med.ctr. records a Core20 share of 84.7%. Rainhill Village Surgery records a Core20 share of 0.0%. Estimated Core20 volume reaches 8,026 patients at Atlas Medical Practice. Targeting must balance high concentration against absolute volume.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
1,078
SMI register
1.24% recorded prevalence
593
Learning disability register
0.68% recorded prevalence
32
Care homes, 1,182 beds
In the PCN catchment
11.7%
Provide unpaid care
St. Helens (LAD), Census 2021
The PCN records 1,078 severe mental illness patients (1.2%) and 593 with learning disabilities (0.7%), both above England (1.0% and 0.6%), alongside 32 catchment care homes (1,182 beds). St. Helens borough reports 20 rough sleepers in 2025 and an 11.7% unpaid care rate. Higher recorded prevalence across vulnerable registers highlights ongoing demand for routine health checks and coordinated care-home provision.
Severe mental illness: physical health checks
Across 1,078 SMI patients (1.2% prevalence), physical health checks trail England on BMI recording (75.0% vs 82.1%), alcohol consumption recording (74.1% vs 81.8%), and blood pressure checks (80.1% vs 83.4%). Addressing these checks could improve physical health monitoring.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
15,893
Hypertension register
+5.90%
Register growth, 3 yrs
St. Helens (LAD) +5.27% · England +5.60%
+1.92pp
BP control, under 80
≤140/90 · +0.08pp aged 80+
+2,187
More patients by 2030
Forecast 18,080 (20.55%)
Hypertension case-finding and control
Recorded hypertension prevalence is 18.3% (15,893 patients), above England (15.2%) and the ICB (16.8%), though below St. Helens (18.7%). Crude rates are not age-adjusted. Blood pressure monitoring reached 87.5%, trailing England (90.0%), St. Helens (87.7%) and the ICB (88.3%). Furthermore, blood pressure control to 140/90 mmHg or less for patients aged under 80 is 65.5%, trailing England (67.8%), St. Helens (65.9%) and the ICB (66.4%). An unverified projection estimates 18,080 patients by 2030 (about 2,200 more). With blood pressure monitoring and under-80 control trailing national benchmarks across a large register, systematic recall audits could support improved blood pressure management.
Lipids and statins
Patients with QRISK ≥ 20% on lipid-lowering therapy reach 64.1%, exceeding England (63.6%), St. Helens (62.1%) and the ICB (63.2%). Statin coverage for diabetes with CVD is 83.8% (England 84.4%). With secondary statin coverage slightly below England, prioritising case reviews for diabetic patients with cardiovascular disease could help close secondary prevention gaps.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 181,583 | £2.00 | £1.71 | £1.86 | £363,166 |
| Cardiovascular (all), 2025 | 266,155 | £4.16 | £4.37 | £3.33 | £1,107,205 |
In 2026, the PCN prescribed 181,583 items for lipid-regulating drugs at £2.00 per item, compared with £1.86 in England, £1.75 in St. Helens, and £1.71 across the ICB. The PCN spends £25,422 more than at England's unit cost and £52,659 more than at ICB unit cost. Higher unit costs suggest potential to review prescribing choices against ICB formulary benchmarks.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+1.14%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.77%
Asthma prevalence, PCN 3-yr % change
Recorded COPD prevalence is 2.8% (2,462 patients; England 1.9%), and asthma prevalence is 8.2% (6,668 patients; England 6.6%). Annual COPD reviews reach 73.0% (England 76.4%). Annual asthma reviews reach 54.5% (England 65.7%), leaving about 3,000 patients unreviewed, while second-hand smoke status recording for ages 6-19 is 65.1% (England 78.8%). Paediatric asthma prescribing reaches 2,933 items per 1,000 aged 5-19 (England 1,488 rate). Expanding proactive asthma reviews could help evaluate care quality alongside elevated paediatric prescribing.
Cancer register and children's immunisation
The cancer register records 3,671 patients (4.2% prevalence vs 3.8% in England). In Q1 2025/26, 24-month MMR dose 1 coverage is 83.3% (England 88.3%, ICB 87.3%). At age 5, MMR dose 1 reaches 95.8% (England 91.7%) while MMR dose 2 is 88.4% (England 82.8%), reflecting a 7.4 pp same-cohort difference that reaches 15.5 pp at Rainbow Medical Centre. Auditing practice recall protocols may identify opportunities to improve second-dose completion before school entry.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
In 2022, 55.5% of staged cancers across NHS Cheshire and Merseyside ICB were diagnosed at stage 1 or 2 (England 55.3%), rising 2.6 pp from 2013 to 2022 but 19.5 pp below the 75.0% national ambition by 2028. Closing this across the ICB requires about 2,640 extra early diagnoses annually across 13,490 cancers with a known stage (72.8%). For the PCN (3,671 cancer patients, 4.2% prevalence), cervical screening coverage is 67.3% (St. Helens 69.2%), down 1.1% over 2023 to 2025 (England -1.0%), with Atlas Medical Practice at 54.6% and The Bowery Medical Centre at 62.6%. Screening shortfalls at lower-uptake practices risk delayed diagnosis.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At Mersey and West Lancashire Teaching Hospitals NHS Trust, 62-day referral to treatment performance is 7.0 pp below the 85.0% standard, while NHS Cheshire and Merseyside ICB is 8.8 pp below. On the 28-day faster diagnosis standard, the trust is 2.6 pp below the 75.0% standard, whereas the ICB is 2.2 pp above. On the 31-day combined treatment standard, the trust is 0.5 pp below the 96.0% standard and the ICB is 0.3 pp below. Secondary care treatment bottlenecks highlight the need for robust practice-level safety-netting and high-quality urgent referrals.
| Pathways within standard (%) | Mersey and West Lancashire | North Cheshire and Mersey | Liverpool | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 72.39 | 80.21 | 75.47 | 77.25 | 79.32 |
| 31-day treatment (96%) | 95.46 | 98.17 | 90.51 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 77.96 | 83.67 | 73.26 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Mersey and West Lancashire | North Cheshire and Mersey | Liverpool | England |
|---|---|---|---|---|
| MRI | 14.04 | 0.53 | 6.42 | 21.40 |
| CT | 13.08 | 2.32 | 0.71 | 9.92 |
| Echocardiography | 34.88 | 28.04 | 12.55 | 28.48 |
| Colonoscopy | 18.04 | 15.98 | 33.14 | 30.83 |
| Gastroscopy | 18.17 | 20.24 | 44.99 | 29.02 |
| All 15 DM01 tests | 21.17 | 6.34 | 11.50 | 23.14 |
| Community services activity | St. Helens residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 48,525 | 541,280 |
| Referrals | 7,815 | 97,150 |
| Patients with a contact | 12,745 | 146,240 |
Community services (residents of St. Helens), Jun 2026 (provisional). In June 2026 (provisional), community services recorded 48,525 contacts with St. Helens borough residents, of which 29,090 were with adults aged 65 and over (a 59.9% share). High contact volume among older residents underscores the priority of coordinating community nursing and supportive cancer care.
Practice variation and patient experience
Overall patient satisfaction varies across a 24.6 percentage-point range between network practices
In 2025/26, England recorded 97.1% achievement in the QOF clinical domain. Rainhill Village Surgery achieved 93.6%, and Atlas Medical Practice achieved 100.0%. In the QOF vaccination and immunisation domain, England recorded 55.2% achievement. Atlas Medical Practice achieved 15.6%, while Eccleston Medical Centre achieved 64.7%, reflecting a range of 49.0 pp between Atlas Medical Practice and Eccleston Medical Centre.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Rainhill Village | 117 | 0.0 | 78.3% | 75.4% | 89.6% |
| Eccleston | 114 | 10.0 | 74.1% | 65.6% | 87.7% |
| Mill Street | 120 | 41.2 | 55.0% | 62.8% | 86.7% |
| Longton | 101 | 1.3 | 64.6% | 60.2% | 82.0% |
| Spinney Medical | 113 | 47.6 | 53.1% | 72.0% | 80.4% |
| Rainbow | 120 | 52.2 | 52.7% | 65.3% | 78.6% |
| Berrymead Family | 110 | 84.7 | 50.9% | 72.9% | 75.3% |
| Four Acre | 101 | 57.2 | 42.9% | 68.0% | 70.0% |
| Bowery | 84 | 59.4 | 57.5% | 82.3% | 67.1% |
| Atlas Medical | 120 | 70.8 | 42.3% | 79.5% | 64.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Across 25 trend measures, 18 trailed England, led by heart failure reviews
Across 25 three-year trend measures, 18 trailed England. In heart failure functional reviews, a relative drop of 7.0% (England +8.7%) lagged national progress. Recording of alcohol consumption in patients with psychosis fell 2.1 pp (England +5.4 pp), while learning disability prevalence fell 4.6% (England +5.4%). Conversely, breast screening rose +10.8% (England +8.4%), and lipid lowering therapy for patients with QRISK ≥ 20% rose +7.9% (England +6.2%). Trailing national trends across routine review measures may reflect recall scheduling gaps; auditing annual review booking intervals across practices would test this.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Learning disability register
Alcohol record (psychosis)
Dementia register
Diabetes HbA1c control
COPD reviews
Breast screening (53-70)
QRISK statin treatment
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | St. Helens (LAD) | Asset | PCN | St. Helens (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 32 (1,182 beds) | n/a | Schools (catchment) | 115 | n/a |
| Children's centres | 7 | 8 | Places of worship | 60 | 90 |
| Libraries | 9 | 15 | Primary schools (LA maintained) | 28 | 32 |
| Primary academies | 8 | 11 | Special schools | 1 | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Proactive asthma review and prescribing recall
Asthma annual reviews reach 54.5% across 6,668 patients (St. Helens 58.2%, ICB 62.3%, England 65.7%), leaving 3,035 (about 3,000) unreviewed, alongside 65.1% second-hand smoke recording (ages 6-19; England 78.8%). For discussion: standardise asthma review recall and inhaler checks, prioritising high-deprivation and high-volume practices. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Bundled SMI physical health check outreach
Across 1,078 SMI patients (1.2% prevalence; 47.4% of the borough register), checks lag England on BMI (75.0% vs 82.1%), alcohol (74.1% vs 81.8%, falling 2.1 pp vs +5.4 pp), and BP (80.1% vs 83.4%). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Pre-school MMR and booster recall
In Q1 2025/26, 24-month MMR1 is 83.3% (ICB 87.3%, England 88.3%), and age-5 MMR1 (95.8%) exceeds MMR2 (88.4%) by 7.4 pp across 216 children (15.5 pp at Rainbow Medical Centre). For discussion: audit pre-school immunisation call-recall lists, offer flexible slots, and focus catch-up on practices with widest dose gaps. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult chronic disease planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Differentiated Core20 outreach model (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI health check recall (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension control recall audits (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR recall (p6) | MMR dose 1 coverage at 24 months | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening uptake initiative (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Triage and phone access review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Proactive asthma review and prescribing recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Bundled SMI physical health check outreach (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Option 3 · Pre-school MMR and booster recall (p12) | MMR dose 1 coverage at 24 months · MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
